Combination of temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 6, 2012, Pages 907-916

  Martin, Bénédicte ^a   Edeline, Julien ^a,b   Patard, Jean Jacques ^a,c   Oger, Emmanuel ^c   Jouan, Florence ^a   Boulanger, Gaëlla ^a   Zerrouki, Sélim ^c   Vigneau, Cécile ^a,c   Rioux Leclercq, Nathalie ^a,c  

^a CNRS   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Anti angiogenic drugs; Clear cell renal cell carcinoma; Combinations

Indexed keywords

SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; SIROLIMUS;

EID: 84864345057     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1162-x     Document Type: Article

References (45)

1. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by Everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98:923-930. doi:10.1038/sj.bjc.6604269
2. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261
3. Choueiri TK, Vaziri SAJ, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J et al (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180:860-866
4. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387-3394
5. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor Temsirolimus. Cancer Res 66:5549-5554
6. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of Sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGFrelated proteins. J Transl Med 5:32. doi:10.1186/1479-5876-5-32
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
8. Faivre S (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35. doi:10.1200/JCO.2005.02.2194
9. Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676. doi:10.1038/nm0603-669
10. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, AVara NA, Ferguson-Smith MA (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173
11. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V (2010) mTOR inhibition by Everolimus counteracts VEGF induction by Sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 296:249-256
12. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90. doi:10.1038/ng0594-85
13. Gossage L, Eisen T (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7:277-288. doi:10.1038/nrclinonc.2010. 42
14. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE (2011) A phase 1 study of Everolimus and Sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117(18):4194-4200. doi:10.1002/cncr.25931
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
16. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014
17. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826
18. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300. doi:10.3322/caac.20073
19. Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115:3618-3630
20. Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL (2008) Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Investig J Tech Methods Pathol 88:962-972. doi:10.1038/labinvest.2008.65
21. Le Tourneau C, Faivre S, Serova M, Raymond E (2008) mTORC1 inhibitors: is Temsirolimus in renal cancer telling us how they really work? Br J Cancer 99:1197-1203. doi:10.1038/sj.bjc. 6604636
22. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858
23. Madri JA, Pratt BM, Tucker AM (1988) Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol 106:1375-1384
24. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1995) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Development 121:4005-4016
25. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res OV J Am Assoc Cancer Res 9:327-337
26. Morimoto AM, Tan N, West K, McArthur G, Toner GC, Manning WC, Smolich BD, Cherrington JM (2004) Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23:1618-1626. doi:10.1038/sj.onc.1207268
27. Motzer RJ, Hutson T, Pharm D, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
28. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N et al (2008) efficacy of Everolimus in advanced renal cell carcinoma: a double- blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
29. Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F et al (2011) Temsirolimus and bevacizumab, or Sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12:673-680
30. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7:225-233
31. Patard J-J, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, Dubourg C, Lobel B, Denis M, Fergelot P (2009) Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 101:1417-1424. doi:10.1038/sj.bjc.6605298
32. Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with Temsirolimus and Sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24-27. doi:10.3816/CGC.2009.n.004
33. Patnaik A (2007) A phase I, pharmacokinetic and pharmacodynamic study of Sorafenib (S), a multi-targeted kinase inhibitor in combination with Temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25:3512 [Abstract]
34. Piguet A-C, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V, Dufour J-FJ (2011) Everolimus augments the effects of Sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10:1007-1017. doi:10.1158/1535-7163.MCT-10-0666
35. Raymond E (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347. doi:10.1200/JCO.2004.08.116
36. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and von Hippel- Lindau gene status. BJU Int 98:756-762
37. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373:1119-1132
38. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729-734. doi:10.1038/nrc1974
39. Soria JC, Massard C, Izzedine H (2009) From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol 27:1359-1361
40. Sosman J, Puzanov I (2009) Combination targeted therapy in advanced renal cell carcinoma. Cancer 115:2368-2375
41. Sosman JA, Puzanov I, Atkins MB (2007) Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13:764s-769s
42. Strumberg D (2004) Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972. doi:10.1200/JCO.2005.06.124
43. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109. doi:10.1158/0008-5472. CAN-04-1443
44. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258
45. Yuen JSP, Sim MY, Siml HG, Chong TW, Lau WKO, Cheng CWS, Huynh H (2011) Inhibition of angiogenic and non-angiogenic targets by Sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer 104:941-947. doi:10.1038/bjc.2011.55